Benzinga's Top #PreMarket Gainers

By: via Benzinga
Akebia Therapeutics (NASDAQ: AKBA) shares gained 19.51% to $20.15 in the pre-market. Credit Suisse initiated coverage on the stock with ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.